Internal and Emergency Medicine

, Volume 12, Issue 5, pp 577–585 | Cite as

Vasculitis for the internist: focus on ANCA-associated vasculitis

  • Benjamin Chaigne
  • Loïc GuillevinEmail author


Vasculitides comprise several diseases affecting vessels of different sizes, mainly arteries, but also capillaries and veins. Antineutrophil cytoplasm antibody-associated vasculitides (AAVs) belong to the systemic necrotizing small-vessel vasculitis group that comprises granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis. Internists often see AAV patients, and although their outcomes are usually good, the disease can be responsible for morbidity and mortality. Herein, after reviewing the literature, we concentrate on selected aspects important for the internist, including classification, diagnostic dilemmas, treatment novelties, and follow-up.


Vasculitis ANCA GPA MPA EGPA HRQoL Rituximab 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Statements of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent



  1. 1.
    Jennette JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603–606. doi: 10.1007/s10157-013-0869-6 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Fraison J-B, Sève P, Dauphin C et al (2016) Kawasaki disease in adults: observations in France and literature review. Autoimmun Rev 15:242–249. doi: 10.1016/j.autrev.2015.11.010 CrossRefPubMedGoogle Scholar
  3. 3.
    Pagnoux C, Carette S, Khalidi NA et al (2015) Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33:S-77–83PubMedPubMedCentralGoogle Scholar
  4. 4.
    Audemard-Verger A, Pillebout E, Guillevin L et al (2015) IgA vasculitis (Henoch-Shönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev 14:579–585. doi: 10.1016/j.autrev.2015.02.003 CrossRefPubMedGoogle Scholar
  5. 5.
    Jachiet M, Flageul B, Deroux A et al (2014) The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of 57 patients. Arthritis Rheumatol (Hoboken, NJ). doi: 10.1002/art.38956 Google Scholar
  6. 6.
    Quartuccio L, Isola M, Corazza L et al (2014) Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford) 53:2209–2213. doi: 10.1093/rheumatology/keu271 CrossRefGoogle Scholar
  7. 7.
    Comarmond C, Pagnoux C, Khellaf M et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270–281. doi: 10.1002/art.37721 CrossRefPubMedGoogle Scholar
  8. 8.
    Chaigne B, Guillevin L (2016) Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides. Clin Exp Rheumatol 34:S121–S128PubMedGoogle Scholar
  9. 9.
    Kussmaul A, Maier R (1866) Uber eine bisher nicht beschriebene eigenthumliche arterienerkran-kung (periarteritis nodosa), die mit morbus brightii und rapid fortschreitender allgemeiner muskellahmung einhergeht. Dtsch Arch Klin Med 1:484–518Google Scholar
  10. 10.
    Wohlwill F (1923) Über die nur mikroskopisch erkennbare Form der Periarteritis nodosa. Virchows Arch Pathol Anat Physiol 246:36CrossRefGoogle Scholar
  11. 11.
    Wegener F (1987) On generalised septic vessel diseases. By Friedrich Wegener, 1937 (translation). Thorax 42:918–919CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hunder GG, Arend WP, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33:1065–1067CrossRefPubMedGoogle Scholar
  13. 13.
    Fries JF, Hunder GG, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 33:1135–1136CrossRefPubMedGoogle Scholar
  14. 14.
    Chaigne B, Terrier B, Thieblemont N et al (2016) Dividing the Janus vasculitis? Pathophysiology of eosinophilic granulomatosis with polyangitis. Autoimmun Rev 15:139–145. doi: 10.1016/j.autrev.2015.10.006 CrossRefPubMedGoogle Scholar
  15. 15.
    Sinico RA, Di Toma L, Maggiore U et al (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52:2926–2935. doi: 10.1002/art.21250 CrossRefPubMedGoogle Scholar
  16. 16.
    Lyons PA, Rayner TF, Trivedi S et al (2012) Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367:214–223. doi: 10.1056/NEJMoa1108735 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Damoiseaux J, Csernok E, Rasmussen N et al (2016) Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. doi: 10.1136/annrheumdis-2016-209507 PubMedGoogle Scholar
  18. 18.
    Csernok E, Moosig F (2014) Current and emerging techniques for ANCA detection in vasculitis. Nat Rev Rheumatol 10:494–501. doi: 10.1038/nrrheum.2014.78 CrossRefPubMedGoogle Scholar
  19. 19.
    Yates M, Watts RA, Bajema IM et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594. doi: 10.1136/annrheumdis-2016-209133 CrossRefPubMedGoogle Scholar
  20. 20.
    Aasarød K, Bostad L, Hammerstrøm J et al (2001) Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrol Dial Transplant 16:953–960CrossRefPubMedGoogle Scholar
  21. 21.
    Devaney KO, Travis WD, Hoffman G et al (1990) Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 14:555–564CrossRefPubMedGoogle Scholar
  22. 22.
    Schnabel A, Holl-Ulrich K, Dalhoff K et al (1997) Efficacy of transbronchial biopsy in pulmonary vasculitides. Eur Respir J 10:2738–2743CrossRefPubMedGoogle Scholar
  23. 23.
    Travis WD, Hoffman GS, Leavitt RY et al (1991) Surgical pathology of the lung in Wegener’s granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 15:315–333CrossRefPubMedGoogle Scholar
  24. 24.
    Berden AE, Ferrario F, Hagen EC et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21:1628–1636. doi: 10.1681/ASN.2010050477 CrossRefPubMedGoogle Scholar
  25. 25.
    Berden AE, Jones RB, Erasmus DD et al (2012) Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 23:313–321. doi: 10.1681/ASN.2011040330 CrossRefPubMedGoogle Scholar
  26. 26.
    Hauer HA, Bajema IM, Hagen EC et al (2002) Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. Nephrol Dial Transpl 17:587–596CrossRefGoogle Scholar
  27. 27.
    Hruskova Z, Honsova E, Berden AE et al (2014) Repeat protocol renal biopsy in ANCA-associated renal vasculitis. Nephrol Dial Transpl 29:1728–1732. doi: 10.1093/ndt/gfu042 CrossRefGoogle Scholar
  28. 28.
    Visconti L, Cernaro V, Ricciardi CA et al (2016) Renal biopsy: still a landmark for the nephrologist. World J Nephrol 5:321–327. doi: 10.5527/wjn.v5.i4.321 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rasmussen N, Jayne D, Abramowicz D et al (1995) European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL. Clin Exp Immunol 101(Suppl 1):29–34Google Scholar
  30. 30.
    Hellmich B, Flossmann O, Gross WL et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617. doi: 10.1136/ard.2006.062711 CrossRefPubMedGoogle Scholar
  31. 31.
    Rosenbaum JT, Choi D, Wilson DJ et al (2015) Orbital pseudotumor can be a localized form of granulomatosis with polyangiitis as revealed by gene expression profiling. Exp Mol Pathol 99:271–278. doi: 10.1016/j.yexmp.2015.07.002 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366:539–551. doi: 10.1056/NEJMra1104650 CrossRefPubMedGoogle Scholar
  33. 33.
    Della-Torre E, Lanzillotta M, Campochiaro C et al (2016) Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: a case report and review of the literature. Medicine (Baltimore) 95:e4633. doi: 10.1097/MD.0000000000004633 CrossRefGoogle Scholar
  34. 34.
    Rachapalli SM, Kiely PDW (2008) Cocaine-induced midline destructive lesions mimicking ENT-limited Wegener’s granulomatosis. Scand J Rheumatol 37:477–480. doi: 10.1080/03009740802192043 CrossRefPubMedGoogle Scholar
  35. 35.
    Borner U, Landis BN, Banz Y et al (2012) Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener’s granulomatosis presenting primarily with sinonasal disease. Am J Rhinol Allergy 26:475–480. doi: 10.2500/ajra.2012.26.3825 CrossRefPubMedGoogle Scholar
  36. 36.
    Holle JU, Gross WL, Holl-Ulrich K et al (2010) Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 69:1934–1939. doi: 10.1136/ard.2010.130203 CrossRefPubMedGoogle Scholar
  37. 37.
    De Groot K, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461–2469. doi: 10.1002/art.21142 CrossRefPubMedGoogle Scholar
  38. 38.
    Thickett DR, Richter AG, Nathani N et al (2006) Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis. Rheumatology (Oxford) 45:261–268. doi: 10.1093/rheumatology/kei217 CrossRefGoogle Scholar
  39. 39.
    Callister MEJ, Baldwin DR, Akram AR et al (2015) British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 70(Suppl 2):ii1–ii54. doi: 10.1136/thoraxjnl-2015-207168 CrossRefPubMedGoogle Scholar
  40. 40.
    Harper L (2013) L42. Morbidity in patients with ANCA-associated vasculitis. Presse Med 42:612–616. doi: 10.1016/j.lpm.2013.01.040 CrossRefPubMedGoogle Scholar
  41. 41.
    Shang W, Ning Y, Xu X et al (2015) Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. doi: 10.1371/journal.pone.0126016 Google Scholar
  42. 42.
    Jones RB, Tervaert JWC, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220. doi: 10.1056/NEJMoa0909169 CrossRefPubMedGoogle Scholar
  43. 43.
    Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232. doi: 10.1056/NEJMoa0909905 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780. doi: 10.1056/NEJMoa1404231 CrossRefPubMedGoogle Scholar
  45. 45.
    Jones RB (2014) Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis. Nephron Clin Pract 128:243–249. doi: 10.1159/000368580 CrossRefPubMedGoogle Scholar
  46. 46.
    Alberici F, Smith RM, Jones RB et al (2015) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 54:1153–1160. doi: 10.1093/rheumatology/keu452 CrossRefGoogle Scholar
  47. 47.
    Holle JU, Dubrau C, Herlyn K et al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71:327–333. doi: 10.1136/ard.2011.153601 CrossRefPubMedGoogle Scholar
  48. 48.
    Specks U, Merkel PA, Seo P et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:417–427. doi: 10.1056/NEJMoa1213277 CrossRefPubMedGoogle Scholar
  49. 49.
    Puéchal X, Pagnoux C, Perrodeau É et al (2016) Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis Rheumatol (Hoboken, NJ) 68:690–701. doi: 10.1002/art.39450 CrossRefGoogle Scholar
  50. 50.
    Miloslavsky EM, Specks U, Merkel PA et al (2015) Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol (Hoboken, NJ) 67:1629–1636. doi: 10.1002/art.39104 CrossRefGoogle Scholar
  51. 51.
    Jones RB, Furuta S, Tervaert JWC et al (2015) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 74:1178–1182. doi: 10.1136/annrheumdis-2014-206404 CrossRefPubMedGoogle Scholar
  52. 52.
    Walsh M, Faurschou M, Berden A et al (2014) Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol 9:1571–1576. doi: 10.2215/CJN.00100114 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Turnbull J, Harper L (2009) Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 23:391–401. doi: 10.1016/j.berh.2009.04.002 CrossRefPubMedGoogle Scholar
  54. 54.
    Conway R, Low C, Coughlan RJ et al (2015) Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 45:156–162. doi: 10.1016/j.semarthrit.2015.05.003 CrossRefPubMedGoogle Scholar
  55. 55.
    Siramolpiwat S, Sakonlaya D (2017) Clinical and histologic features of Azathioprine-induced hepatotoxicity. Scand J Gastroenterol. doi: 10.1080/00365521.2017.1311936 PubMedGoogle Scholar
  56. 56.
    Roberts DM, Jones RB, Smith RM et al (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60–65. doi: 10.1016/j.jaut.2014.11.009 CrossRefPubMedGoogle Scholar
  57. 57.
    Mélet J, Mulleman D, Goupille P et al (2013) Rituximab-induced T-cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. doi: 10.1002/art.38107 PubMedGoogle Scholar
  58. 58.
    Martin-Garrido I, Carmona EM, Specks U, Limper AH (2013) Pneumocystis pneumonia in patients treated with rituximab. Chest 144:258–265. doi: 10.1378/chest.12-0477 CrossRefPubMedGoogle Scholar
  59. 59.
    Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548. doi: 10.1002/art.33361 CrossRefPubMedGoogle Scholar
  60. 60.
    Slot MC, Tervaert JWC, Boomsma MM, Stegeman CA (2004) Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 51:269–273. doi: 10.1002/art.20234 CrossRefPubMedGoogle Scholar
  61. 61.
    Thai L-H, Charles P, Resche-Rigon M et al (2014) Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener’s) relapses? Results of a retrospective study on 126 patients. Autoimmun Rev 13:313–318. doi: 10.1016/j.autrev.2013.11.003 CrossRefPubMedGoogle Scholar
  62. 62.
    Shi Y-Y, Li Z-Y, Zhao M-H, Chen M (2015) The CD4 lymphocyte count is a better predictor of overall infection than the total lymphocyte count in ANCA-associated vasculitis under a corticosteroid and cyclophosphamide regimen: a retrospective cohort. Medicine (Baltimore) 94:e843. doi: 10.1097/MD.0000000000000843 CrossRefGoogle Scholar
  63. 63.
    Goupil R, Brachemi S, Nadeau-Fredette A-C et al (2013) Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 8:416–423. doi: 10.2215/CJN.07300712 CrossRefPubMedGoogle Scholar
  64. 64.
    Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16–20. doi: 10.1056/NEJM199607043350103 CrossRefPubMedGoogle Scholar
  65. 65.
    Zycinska K, Wardyn KA, Zielonka TM et al (2009) Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res 14(Suppl 4):265–267CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Guillevin L, Guittard T, Bletry O et al (1987) Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung 165:165–172CrossRefPubMedGoogle Scholar
  67. 67.
    Konishi M, Koarada S, Yamaguchi K et al (2011) Case of microscopic polyangiitis and giant cell arteritis after influenza vaccination. Nihon Rinsho Meneki Gakkai Kaishi 34:154–161CrossRefPubMedGoogle Scholar
  68. 68.
    Stassen PM, Sanders J-SF, Kallenberg CGM, Stegeman CA (2008) Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transpl 23:654–658. doi: 10.1093/ndt/gfm640 CrossRefGoogle Scholar
  69. 69.
    Duggal T, Segal P, Shah M et al (2013) Antineutrophil cytoplasmic antibody vasculitis associated with influenza vaccination. Am J Nephrol 38:174–178. doi: 10.1159/000354084 CrossRefPubMedGoogle Scholar
  70. 70.
    Holvast A, Stegeman CA, Benne CA et al (2009) Wegener’s granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 68:873–878. doi: 10.1136/ard.2008.092924 CrossRefPubMedGoogle Scholar
  71. 71.
    Holvast A, de Haan A, van Assen S et al (2010) Cell-mediated immune responses to influenza vaccination in Wegener’s granulomatosis. Ann Rheum Dis 69:924–927. doi: 10.1136/ard.2009.112813 CrossRefPubMedGoogle Scholar
  72. 72.
    Groh M, Puéchal X, Terrier B et al (2016) VAC-04—Echec de la vaccination antipneumococcique en phase d’attaque du traitement des vascularites à ANCA: l’étude pneumovas pilote 1. Med Mal Infect 46:111. doi: 10.1016/S0399-077X(16)30530-3 CrossRefGoogle Scholar
  73. 73.
    Sangle SR, Vounotrypidis P, Briley A et al (2015) Pregnancy outcome in patients with systemic vasculitis: a single-centre matched case-control study. Rheumatology (Oxford) 54:1582–1586. doi: 10.1093/rheumatology/kev018 CrossRefGoogle Scholar
  74. 74.
    Huong DL, Amoura Z, Duhaut P et al (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29:2571–2576PubMedGoogle Scholar
  75. 75.
    Grygiel-Górniak B, Puszczewicz M (2015) Granulomatosis with polyangiitis in pregnancy—clinical implications and treatment possibilities. Eur Rev Med Pharmacol Sci 19:2331–2335PubMedGoogle Scholar
  76. 76.
    Pagnoux C, Le Guern V, Goffinet F et al (2011) Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. Rheumatology (Oxford) 50:953–961. doi: 10.1093/rheumatology/keq421 CrossRefGoogle Scholar
  77. 77.
    Guillevin L, Pagnoux C, Seror R et al (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90:19–27. doi: 10.1097/MD.0b013e318205a4c6 CrossRefGoogle Scholar
  78. 78.
    Bourgarit A, Le Toumelin P, Pagnoux C et al (2005) Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84:323–330CrossRefGoogle Scholar
  79. 79.
    Pagnoux C, Quéméneur T, Ninet J et al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol (Hoboken, NJ) 67:1117–1127. doi: 10.1002/art.39011 CrossRefGoogle Scholar

Copyright information

© SIMI 2017

Authors and Affiliations

  1. 1.Department of Internal Medicine, Hôpital Cochin, APHPUniversité Paris DescartesParis Cedex 14France

Personalised recommendations